Showing results (11-20 of 43) with videos related to

Sort By:
Pageof 5
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care|December 24, 2016
Cost-effectiveness analysis of the use of daclatasvir + sofosbuvir + ribavirin (16 weeks and 12 weeks) vs sofosbuvir + ribavirin (16 weeks and 24 weeks) for the treatment of cirrhotic patients affected with hepatitis C virus genotype 3 in ItalyUmberto Restelli, Alfredo Alberti, Adriano Lazzarin, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|August 25, 2020
Cost of illness of Primary Biliary Cholangitis - a population-based studyAlessio Gerussi, Umberto Restelli, Davide Croce, et al.
Therapeutics and Clinical Risk Management|July 20, 2017
Cost-effectiveness analysis of dolutegravir plus backbone compared with raltegravir plus backbone, darunavir+ritonavir plus backbone and efavirenz/tenofovir/emtricitabine in treatment naïve and experienced HIV-positive patientsUmberto Restelli, Giuliano Rizzardini, Andrea Antinori, et al.
Acta Tropica|December 8, 2009
Cost-effectiveness of a successful schistosomiasis control programme in Cambodia (1995-2006)Davide Croce, Emanuele Porazzi, Emanuela Foglia, et al.
Journal of Neurosurgical Sciences|March 28, 2019
An observational analysis of costs and effectiveness of an intraoperative compared with a preoperative image-guided system in spine surgery fixation: analysis of 10 years of experienceUmberto Restelli, Carla D Anania, Emanuele Porazzi, et al.
Frontiers in Nutrition|July 30, 2026
A multicentric retrospective pilot study on the clinical, nutritional, economic and organizational impact of an integrated protocol for dysphagia management within nursing homes in ItalyAntonio Sebastiano, Chiara Mazzetti, Umberto Restelli, et al.
Clinicoeconomics and Outcomes Research : CEOR|September 14, 2012
Cost of human immunodeficiency virus infection in Italy, 2007-2009: effective and expensive, are the new drugs worthwhile?Giuliano Rizzardini, Umberto Restelli, Paolo Bonfanti, et al.
Clinicoeconomics and Outcomes Research : CEOR|August 12, 2024
Health Technology Assessment for Fast-Track Elective Knee and Hip Arthroplasty in a High-Volume Orthopaedic Hospital in ItalyUmberto Restelli, Jacopo Vitale, Edoardo Croce, et al.
Cancer Management and Research|December 22, 2017
Economic burden of the management of metastatic castrate-resistant prostate cancer in Italy: a cost of illness studyUmberto Restelli, Giovanni Luca Ceresoli, Davide Croce, et al.
Jac-Antimicrobial Resistance|April 24, 2023
Cost analysis of dalbavancin versus standard of care for the treatment of acute bacterial skin and skin structure infections (ABSSSIs) in two Italian hospitalsFrancesca Bai, Maria Mazzitelli, Sofia Silvola, et al.
Pageof 5